Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 2

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Plasma cell 1Dermatologic 1

Conditions

Neoplasms 4Neoplasm Metastasis 3Urinary Bladder Neoplasms 2Recurrence 2Urethral Neoplasms 1Ureteral Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Multiple Myeloma 1Melanoma 1Carcinoma, Transitional Cell 1Carcinoma in Situ 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × ALT-801 × Clear all
NCT01625260 2024-07-19

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Altor BioScience

Phase 1/2 Terminated
12 enrolled 13 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Recurrence

NCT01326871 2024-06-25

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Altor BioScience

Phase 1/2 Completed
68 enrolled 13 charts
Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis, Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT01670994 2024-06-18

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Altor BioScience

Phase 1/2 Terminated
6 enrolled 10 charts
Plasma cell

Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Recurrence

NCT01029873 2016-10-27

QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma

Altor BioScience

Phase 1/2 Completed
25 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡